All data are based on the daily closing price as of October 7, 2026
h
Hanmi Pharm. Co.
128940.KO
398.92 USD
8.26
+2.11%
Overview
Last close
398.92 usd
Market cap
5.06B usd
52 week high
431.89 usd
52 week low
152.93 usd
Target price
493.05 usd
Valuation
P/E
N/A
Forward P/E
N/A
Price/Sales
4.0931
Price/Book Value
4.7003
Enterprise Value
4.94B usd
EV/Revenue
3.9909
EV/EBITDA
16.5057
Key financials
Revenue TTM
1.24B usd
Gross Profit TTM
737.02M usd
EBITDA TTM
280.81M usd
Earnings per Share
N/A usd
Dividend
1.49 usd
Total assets
1.51B usd
Net debt
128.62M usd
About
Hanmi Pharm. Co., Ltd., a biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally. It focuses on research areas with high unmet medical needs, including obesity, metabolism, oncology, and rare diseases. The company's products include Gugutams, a urological combination therapy combining two active ingredients: tamsulosin, a treatment for Obstructive Prostatic Growth (OPG), and tadalafil, a treatment for erectile dysfunction (ED). The company has a research collaboration with MEDIC Life Sciences Inc. to identify cancer biomarkers. The company was founded in 1973 and is based in Hwaseong-si, South Korea.